Evidence map›Paper›PMID 38527997›Full record

ArticleNature communications2024

Phenome-wide Mendelian randomisation analysis of 378,142 cases reveals risk factors for eight common cancers.

Molly Went, Amit Sud, Charlie Mills, Abi Hyde, Richard Culliford, Philip Law, Jayaram Vijayakrishnan, Ines Gockel, Carlo Maj, Johannes Schumacher and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Genome-wide association studies and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2024
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Molly Went *Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. molly.went@icr.ac.uk.ORCID http://orcid.org/0000-0003-3271-975X
Amit Sud *Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-6133-0164
Charlie Mills *Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-4755-7549
Abi Hyde *Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0009-0006-8868-492X
Richard CullifordDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Philip LawDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-9663-4611
Jayaram VijayakrishnanDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-8284-2249
Ines GockelDepartment of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig, Leipzig, Germany.ORCID http://orcid.org/0000-0001-7423-713X
Carlo MajCenter for Human Genetics, University Hospital of Marburg, Marburg, Germany.ORCID http://orcid.org/0000-0002-9559-1725
Johannes SchumacherCenter for Human Genetics, University Hospital of Marburg, Marburg, Germany.ORCID http://orcid.org/0000-0001-9217-6457
Claire PallesInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0002-9670-2263
Martin KaiserDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-3677-4804
Richard HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-5268-0242

Funding

Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098758 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2003 to 2010
$11.0M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098233 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNTER, DAVID JOHN · 2003 to 2010
$10.8M
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
Epidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098216 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI RIBOLI, ELIO · 2003 to 2011
$7.4M
A genome-wide association study for breast cancer in BRCA1 mutation carriersR01CA128978 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2008 to 2012
$4.8M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.U01CA098710 · NCI · AMERICAN CANCER SOCIETY, INC. · PI GAPSTUR, SUSAN M · 2003 to 2011
$4.2M
Imputation-based approach to identify low frequency variants in prostate cancerU01CA188392 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SCHUMACHER, FREDRICK RAY · 2014 to 2016
$1.9M
NCI NIH HHS R01 CA128978NCI NIH HHS U01 CA098216NCI NIH HHS U01 CA098233NCI NIH HHS U01 CA098710NCI NIH HHS U01 CA098758NCI NIH HHS U01 CA188392NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148537NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008IWellcome Trust 227000
6 · The paper itself

Abstract

For many cancers there are only a few well-established risk factors. Here, we use summary data from genome-wide association studies (GWAS) in a Mendelian randomisation (MR) phenome-wide association study (PheWAS) to identify potentially causal relationships for over 3,000 traits. Our outcome datasets comprise 378,142 cases across breast, prostate, colorectal, lung, endometrial, oesophageal, renal, and ovarian cancers, as well as 485,715 controls. We complement this analysis by systematically mining the literature space for supporting evidence. In addition to providing supporting evidence for well-established risk factors (smoking, alcohol, obesity, lack of physical activity), we also find sex steroid hormones, plasma lipids, and telomere length as determinants of cancer risk. A number of the molecular factors we identify may prove to be potential biomarkers. Our analysis, which highlights aetiological similarities and differences in common cancers, should aid public health prevention strategies to reduce cancer burden. We provide a R/Shiny app to visualise findings.

Indexed as

Genome-Wide Association StudyOvarian NeoplasmsFemaleHumansMaleMendelian Randomization AnalysisPhenomicsPhenotypePolymorphism, Single NucleotideRisk Factors

Identifiers

PMID38527997
PMCPMC10963765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.